Kristalose Shortage: What Providers and Prescribers Need to Know in 2026

As prescribers and clinical teams manage increasingly complex medication supply environments, even a seemingly straightforward medication like Kristalose (lactulose powder for oral solution) can generate unexpected workflow challenges. When patients cannot fill their prescription, they often turn first to their provider — and being prepared with clinical guidance and practical resources is essential.

This guide provides an evidence-based clinical overview for gastroenterologists, hepatologists, PCPs, NPs, and PAs on what to know about Kristalose availability in 2026 — and how to support patients who cannot access their prescription.

Current FDA Shortage Status and Background

Kristalose is not currently listed on the FDA's drug shortage database (fda.gov/drug-shortages) as of 2026. The active ingredient — lactulose — has FDA approval dating to 1977 and is available in multiple forms. The availability challenges patients encounter with Kristalose are primarily structural: it is a brand-name product manufactured by a single entity (Cumberland Pharmaceuticals Inc., Nashville, TN), which creates dependency on one supply chain. Generic lactulose oral solution is produced by multiple manufacturers and remains broadly available.

Pharmacy databases including Drugs.com explicitly flag that Kristalose availability can be inconsistent due to "stock shortages and other unknown variables." Clinicians seeing patients who report inability to fill Kristalose should take these reports seriously, even in the absence of a formal FDA designation.

Clinical Indications and Who Is Prescribed Kristalose

Kristalose (as the powder packet form) carries FDA approval for chronic constipation in adults. Importantly, the powder formulation may be preferred for specific clinical populations:

Elderly patients who have difficulty measuring syrup, have spills, or prefer the portability of single-dose packets

Patients with motor impairments or hand tremors who cannot reliably use a measuring cup

Patients with documented intolerance to the syrup vehicle (e.g., sensitivity to additives in certain liquid formulations)

Travel or activity-related situations where refrigeration of liquid is not possible

Note: Lactulose solution (not the Kristalose powder form) also carries FDA approval for the prevention and treatment of portal-systemic encephalopathy (PSE) including hepatic pre-coma and coma. Kristalose powder is indicated only for constipation; patients with PSE should be receiving lactulose solution.

Therapeutic Substitution Guidance for Constipation Indication

For patients taking Kristalose for chronic constipation who cannot fill their prescription, the following substitutions are clinically appropriate, listed in order of therapeutic similarity:

1. Generic lactulose oral solution (10g/15 mL) — The most direct substitution. Same active ingredient, same mechanism, same clinical efficacy. Universally available. Typical dosing: 15–30 mL (10–20g) daily. Document the reason for switching and confirm patient understanding of measuring instructions.

2. Polyethylene glycol 3350 (MiraLAX) — OTC osmotic laxative with similar efficacy to lactulose for constipation. A Cochrane review found PEG superior to lactulose on outcomes including stool frequency, stool form, and relief of abdominal pain. PEG causes less gas and bloating, which improves adherence. Standard dose: 17g dissolved in 8 oz liquid once daily. Note OTC labeling is for 7 days; off-label chronic use is common and supported by evidence.

3. Other osmotic or stimulant laxatives — For short-term bridging: senna (8.6–17.2mg at bedtime) or bisacodyl (5–10mg orally). These are generally not preferred for chronic constipation management due to tolerability and theoretical long-term concerns.

Formulary and Insurance Considerations

Most commercial insurance plans and Medicare Part D formularies cover generic lactulose at Tier 1 or Tier 2 with low or no copay. Brand-name Kristalose is typically either not covered or requires step therapy, prior authorization, or a specific clinical justification for the brand over generic.

If a patient has a medical necessity for the powder packet format specifically (e.g., documented motor impairment preventing accurate liquid measurement), a prior authorization request citing clinical need may be warranted. Cumberland Pharmaceuticals also offers a manufacturer coupon reducing out-of-pocket costs to as low as $5 per month for commercially insured patients.

Key Drug Interactions and Contraindications to Review During Substitution

Before authorizing any lactulose formulation, confirm:

Patient is not on a low-galactose diet or has galactosemia (absolute contraindication)

Monitor for electrolyte imbalances if patient is on lactulose longer than 6 months or is elderly/debilitated

Non-absorbable antacids (aluminum hydroxide, calcium carbonate, sodium bicarbonate) may inhibit the desired pH drop — counsel patients to separate timing

Warfarin: lactulose may enhance anticoagulant effect — monitor INR after any change in lactulose dose or formulation

Patients undergoing electrocautery procedures (colonoscopy, proctoscopy) should be instructed on bowel prep considerations due to H2 gas accumulation risk

Tools to Help Your Patients Find Kristalose

For practices managing multiple patients on Kristalose, medfinder for providers is a service that calls local pharmacies to identify which ones can fill a specific prescription. Rather than having your office staff spend hours on hold, medfinder handles outreach and returns results by text. This is particularly useful for high-acuity patients such as those with hepatic encephalopathy who cannot tolerate medication gaps.

Summary Recommendations for Providers

When a patient cannot find Kristalose, prescribe generic lactulose oral solution as a therapeutic equivalent — same active ingredient, equivalent dose

For constipation-only indication, PEG 3350 (MiraLAX) is a clinically appropriate alternative with potentially better tolerability

For hepatic encephalopathy: only switch to generic lactulose — do not substitute PEG or stimulant laxatives

Document any formulary-based switches and confirm patient adherence during transitions

Refer high-risk patients to medfinder for pharmacy location assistance